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Abstract
Background: The purpose of this study was to evaluate the impact of recombinant human
erythropoietin (rHuEPO) use for anemia of critical illness at a practice site where delayed initiation
is common.
Methods:  Retrospective medical record review involving patients treated with rHuEPO for
anemia of critical illness. Those patients given rHuEPO or diagnosed with end-stage renal disease
(ESRD) prior to ICU admission were excluded. The primary endpoints were rHuEPO use and RBC
transfusion patterns.
Results: Complete data were collected for consecutive admissions of 126 patients. Average age
(SD) and APACHE II score were 56.5 (18.6) years and 25 (7.8), respectively. The median ICU (IQR)
and hospital length of stay (LOS) were 24 (11.25, 39) and 29 (17, 44.75) days, respectively.
Treatment with rHuEPO was started an average of 12.5 +/- 10.5 days after ICU admission and given
for 3.8 +/- 3.8 doses. Eighty percent of patients were transfused with an average total of 5.42 +/-
5.08 units received. RBC exposure inversely correlated with a lower mean hemoglobin response
to rHuEPO. ICU LOS (p < 0.0001), hemoglobin at 24 hours (p = 0.055), transfusion within 48 hours
of admit (p < 0.0001), and postoperative status (p = 0.019) were the best predictors of transfusion
requirements (r2 = 0.37).
Conclusion: Delayed initiation of rHuEPO for anemia of critical illness resulted in comparable
hemoglobin and transfusion benefits. Future studies are needed to establish clinical benefit and role
in therapy. RBC exposure may blunt the erythropoietic effects of rHuEPO, potentially frustrating
benefits to those of greatest apparent need.
Background
Anemia of critical illness is a deficiency of blood oxygen-
carrying capacity that is clinically characterized by dimin-
ished tissue oxygenation and complicated by end-organ
dysfunction. The etiology may be categorized into blood
loss and reduced red blood cell (RBC) production.
Trauma, surgery, hemorrhagic complications, and lab
draws compound the effects of functional iron deficiency
and blunted erythropoietic response. The incidence and
course are obscured by RBC transfusion; however, the
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average hemoglobin value on admission to the intensive
care unit (ICU) is 11 g/dL and tends to approach 10 g/dL
at 14 days [1,2].
Allogeneic RBC transfusion is currently one of the princi-
pal interventions for acute treatment of anemia of critical
illness. Sixty to seventy percent of patients that remain in
the ICU beyond 7 days are given RBCs, and critically ill
patients receive an average of one to two units per week
[1,2]. The severity of anemia and degree of RBC exposure
are independently associated with substantially higher
risks of morbidity and mortality [1-3].
Recombinant human erythropoietin (rHuEPO) is widely
used to promote RBC production and reduce transfusion
in the ICU based on a randomized controlled trial (RCT)
by Corwin et al. [4]. However, the clinical benefits of
rHuEPO remain to be satisfactorily enumerated, prior to
establishing cost-effectiveness [5,6]. The actual effects of
rHuEPO may differ on the basis that general use com-
monly deviates from the protocols and patient popula-
tions of controlled trials. We observed that rHuEPO use at
our institution is frequently delayed and prolonged com-
pared to the largest RCT. The purpose of this study is to
evaluate the impact of rHuEPO use for anemia of critical
illness at a practice site where delayed initiation is com-
mon.
Methods
This was a retrospective medical record review conducted
at a 365-bed academic medical center upon the approval
of the IRB. The institution's human subjects committee
granted the study exempt status and informed consent
was not needed.
Population
Patients admitted to adult medical or surgical ICUs and
treated with rHuEPO for anemia of critical illness between
August 1, 2003 and January 15, 2005 were included in the
study. Those patients given rHuEPO or diagnosed with
end-stage renal disease (ESRD) prior to ICU admission
were excluded.
Design
Potential subjects were identified through a central phar-
macy program and ICD-9 codes. Demographic, labora-
tory, and clinical data for consecutive admissions were
collected from the chart and electronic sources, including
age, sex, admit diagnoses, medical history, baseline
APACHE II and SAPS II scores, rHuEPO and iron admin-
istration, RBC transfusion and indication, daily nadir
hemoglobin, and ICU length of stay (LOS). The primary
endpoints evaluated were rHuEPO use and RBC transfu-
sion patterns during ICU stay.
Statistical Analysis
From the data collection forms, data was inputted into
Microsoft Access for manipulation and compilation of
descriptive statistics for the primary endpoint looking at
prescribing and transfusion patterns. Intercooled Stata 7.0
(Stata Corporation, College Station, Texas) was used for
all other statistical analyses.
Bivariate and multivariate regression analyses were used
to evaluate continuous (e.g., age, nadir systolic blood
pressure within 24 hours of transfusion, nadir hemo-
globin within 24 hours of transfusion, APACHE II score,
number of epoetin doses) and dichotomous (e.g., sex,
admission to medical or surgical service, iron administra-
tion) predictors of transfusion requirements. ANOVA was
used to compare hemoglobin concentrations prior to
rHuEPO and at two and four weeks following rHuEPO
administration. Significance was defined as p < 0.05 for all
tests.
Results
Complete data were collected for 126 patients. Average
(SD) age and APACHE II score were 56.5 (18.6) years and
25 (7.8), respectively. Patients were evenly divided
between medical and surgical ICUs and were most com-
monly admitted for respiratory failure, hemodynamic
instability, post-operative, and trauma diagnoses. The
median (IQR) ICU and hospital length of stay were 24
(11.25, 39) and 29 (17, 44.75) days, respectively.
Treatment with rHuEPO was started an average of 12.5 ±
10.5 days after ICU admission and given for 3.8 ± 3.8
doses (Table 1). An average of 120,000 ± 107,323 units of
rHuEPO were administered per patient treatment course
at an estimated cost of 1,200 ± 1,073 U.S. dollars. Iron
studies were performed on 19.0% of patients and 39.7%
of patients concomitantly received iron supplementation.
Eighty percent of patients were given at least one RBC
transfusion in the ICU. Patients received an average of 2.5
± 2.3 transfusions in the ICU for an average total of 5.42
± 5.08 units of RBCs or 3.00 ± 3.69 units of RBCs prior to
initiation of rHuEPO and 2.42 ± 2.98 units. Transfusion
Table 1: Course of Hospital Admission
N = 126 Mean (SD) Median (IQR)
ICU LOS 28.8 (24.8) 24 (11.25, 39)
Hospital LOS 35.1 (30.3) 29 (17, 44.75)
Nadir hemoglobin (g/dL) 7.71 (0.94) 7.75 (7.3,8.3)
rHuEPO
Start day (from ICU 
admit)
12.5 (8.2) 8 (6, 15)
Number of doses 3.8 (3.8) 3 (1, 4)
Days of treatment 23.24 (21.73) 14 (1, 22)BMC Blood Disorders 2007, 7:1 http://www.biomedcentral.com/1471-2326/7/1
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was associated with a diminishing response to rHuEPO
such that incrementally higher RBC exposure inversely
correlated to a lower mean response in hemoglobin at 7
and 14 days after initiation of rHuEPO (Figure 1).
The mean hemoglobin was 11.06 ± 2.52 on ICU admis-
sion, 8.92 ± 0.96 the day of rHuEPO initiation, 10.09 ±
1.42 at 14 days after starting rHuEPO, and 10.08 ± 1.42 at
ICU discharge. The mean change in hemoglobin was 1.15
g/dL (p < 0.0001) at 14 days and 1.22 g/dL (p = 0.0003)
at 28 days after initiation of rHuEPO.
Four independent variables had statistically significant
relationships with transfusion requirements (i.e. units
transfused) using simple linear regression: length of ICU
stay (p < 0.0001) with an R squared of 0.19, length of hos-
pital stay (p < 0.0001) with an R squared of 0.20, APACHE
II score (p = 0.01) with an R squared of 0.05, and the
number of epoetin doses administered (p < 0.0001) with
an R squared of 0.1. Using multiple linear regression the
best model with an adjusted R squared of 0.37 involved
the following independent variables as predictors of trans-
fusion requirements: length of ICU stay (p < 0.0001),
hemoglobin concentration at 24 hours (p = 0.055), trans-
fusion within 48 hours of admit (p < 0.0001), and post-
operative status (p = 0.019).
There was a significant increase in hemoglobin concentra-
tions immediately preceding epoetin administration com-
pared to hemoglobin concentrations at 2 and 4 weeks
after epoetin administration (8.9 g/dL, 10.1 g/dL, and
10.4, respectively, p < 0.0001).
Discussion
In contrast to the largest RCT by Corwin et al, rHuEPO use
at our institution appeared to be reserved for patients with
a substantially greater severity of illness, ICU LOS, and
transfusion burden [4]. The most striking difference in
treatment practices was the marked delay in starting
rHuEPO such that average initiation was nearly ten days
later than that established by the RCT. However, the pro-
longed ICU LOS experienced by patients in this study
resulted in an average of 1.24 additional dosages received
compared to the RCT. There was a 30% higher incidence
of transfusion and a more than twofold greater average
total volume of RBCs given compared to the RCT. The
average change in hemoglobin from baseline (pre-
rHuEPO) to 28 days (1.44 ± 1.62 g/dL) after starting
rHuEPO was similar to that found in the RCT. Further, the
transfusion requirements found in the RCT for placebo vs.
rHuEPO (3.0 vs. 2.4) were identical to those observed pre-
vs. post-rHuEPO (3.0 vs. 2.4). These similarities in trans-
fusion patterns and hemoglobin response are similar
despite the substantial disparities in rHuEPO use and
severity of illness.
One of the most intriguing findings was the apparent
inverse correlation between transfusion and hemoglobin
Hemoglobin changes relative to number of units of red blood cells transfused Figure 1
Hemoglobin changes relative to number of units of red blood cells transfused.
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response to rHuEPO. Corwin et al have consistently noted
substantially higher hemoglobin levels in patients treated
with rHuEPO, despite greater transfusion exposure to pla-
cebo groups [4,7,8]. The simplest explanation of this phe-
nomenon is that rHuEPO produces higher hemoglobin
levels that result in fewer transfusions. Conversely, trans-
fusion may have a blunting effect on erythropoiesis that
depresses hemoglobin levels and leads to additional
transfusions, as scattered reports suggest [9-11]. In effect,
rHuEPO may help break the cycle of diminishing hemo-
globin, consequent transfusion, blunted erythropoiesis,
and further transfusion. Consequently, however, those
patients that experience the greatest transfusion burden
and, therefore, have the greatest appeal for medical inter-
vention may derive the least benefit from rHuEPO.
Clearly, the relationship between rHuEPO, erythropoie-
sis, transfusion, and hemoglobin is extremely complex
and warrants further examination based on this and other
hypothesis-generating findings.
The principal limitations of our study stem from the retro-
spective observational design and the lack of a control
group; however, concerted efforts were made to reduce
potential bias and inaccuracy. First, an emphasis was
given to gathering objective data that was prospectively
collected (e.g. hemoglobin levels). Second, subjects with
complete medical records were enrolled by consecutive
admission to minimize selection bias and the possibility
of data omission.
Conclusion
The use of rHuEPO in clinical practice may vastly vary
from the model of the RCT. However, delayed initiation
of rHuEPO for anemia of critical illness appeared to result
in comparable hemoglobin and transfusion benefits. In
order to maximize the potential benefit of rHuEPO it is
essential to identify patients at greatest risk of a prolonged
ICU course and transfusion burden. Further, RBC expo-
sure may blunt the erythropoietic effects of rHuEPO,
potentially frustrating benefits to those of greatest appar-
ent need.
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